Anticancer Activity of Liposomes Prepared Solely From Cardiolipin
Lipids · 10.08.2026
DOI: 10.1002/lipd.70075 ↗Kurz gefasst
Fachartikel in der Zeitschrift Lipids, online erschienen am 10.08.2026. Verfasst von Arisa Sakamoto und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Technology, Kumamoto Health Science University, Kumamoto, Japan. Die Arbeit nennt 25 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Despite notable medical advancements, the continuous development of novel cancer therapies remains imperative. In this study, we aimed to evaluate the anticancer activity of liposomes prepared solely from nonnatural myristoylated (saturated C 14 chains) or natural cardiolipin to develop a cancer therapies strategy. We calculated IC 50 values using a cell proliferation inhibition assay and investigated the underlying mechanisms in cells exhibiting high inhibitory activity using Western blotting and flow cytometry. Calculation of the IC 50 revealed that liposomes prepared solely with natural cardiolipin exhibited low toxicity to normal cells (> 100 μM) and showed the strongest toxicity against cancer cells, specifically KMS‐12‐PE (multiple myeloma cells) (23.5 ± 11.4 μM) among various cancer cells. In contrast, liposomes prepared solely with myristoylated cardiolipin exhibited weak anticancer activity. Furthermore, the mechanism of anticancer activity was evaluated using immunoblotting and flow cytometry. After administration of natural cardiolipin liposomes, CASPASE‐3 cleavage was confirmed in KMS‐12‐PE cells, and the annexin V‐positive rate was higher than in the liposome‐free control group, suggesting apoptosis induction. These results indicate that natural cardiolipin is nontoxic to normal cells and possesses anticancer activity. This study demonstrated that liposomes formulated with cardiolipin can induce anticancer activity independently. This new finding is considered a foundation for future therapeutic strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Technology, Kumamoto Health Science University, Kumamoto, Japan.
- Medicinal and Biological Chemistry Science Farm Joint Research Laboratory, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
- Department of Hematology, Rheumatology, and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan.
- Science Farm Ltd., Kumamoto, Japan.
- Department of Molecular Biology and Genetics, Burdur Mehmet Akif Ersoy University, Burdur, Turkey.
ORCID-Profile: Nao Nishimura, Takaaki Ito
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Sakamoto, A., Noboruo, I., Tateishi, H., Tomita, S., Fukuda, T., Matsushima-Nagata, K., Aoki, M., Kusakari, D., Masunaga, T., Nishimura, N., Ito, T., Otsuka, M., Fujita, M., & Anraku, K. (2026). Anticancer Activity of Liposomes Prepared Solely From Cardiolipin. Lipids. https://doi.org/10.1002/lipd.70075
Vancouver
Sakamoto A, Noboruo I, Tateishi H, Tomita S, Fukuda T, Matsushima-Nagata K, et al. Anticancer Activity of Liposomes Prepared Solely From Cardiolipin. Lipids. 2026. doi:10.1002/lipd.70075
BibTeX
@article{Sakamoto2026,
author = {Sakamoto, Arisa and Noboruo, Ippei and Tateishi, Hiroshi and Tomita, Sho and Fukuda, Tomoki and Matsushima-Nagata, Kazumi and Aoki, Manabu and Kusakari, Daichi and Masunaga, Takuya and Nishimura, Nao and Ito, Takaaki and Otsuka, Masami and Fujita, Mikako and Anraku, Kensaku},
title = {Anticancer Activity of Liposomes Prepared Solely From Cardiolipin},
journal = {Lipids},
year = {2026},
doi = {10.1002/lipd.70075}
}
EUVIMED